Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard F Kefford

Showing results (1-10 of 139) with videos related to

Pageof 14
Sort By:
The Medical Journal of Australia|November 6, 2012
Drug treatment for melanoma: progress, but who pays? CommentRichard F Kefford
The Medical Journal of Australia|June 14, 2006
Medical heat for climate changeRichard F Kefford
The Medical Journal of Australia|August 21, 2012
Drug treatment for melanoma: progress, but who pays?Richard F Kefford
Current Opinion in Oncology|February 26, 2003
Is there a role for genetic testing in patients with melanoma?Richard F Kefford, Graham J Mann
ANZ Journal of Surgery|January 22, 2003
Targeting molecular mechanisms in cancerRosemary L Balleine, Richard F Kefford
Cell Cycle (Georgetown, Tex.)|February 11, 2005
Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosisStuart Gallagher, Richard F Kefford, Helen Rizos
Cell Cycle (Georgetown, Tex.)|May 7, 2005
p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partnersHelen Rizos, Sarah Woodruff, Richard F Kefford
The International Journal of Biochemistry & Cell Biology|April 8, 2006
The ARF tumour suppressorStuart J Gallagher, Richard F Kefford, Helen Rizos
Lancet (London, England)|August 4, 2009
Cutaneous melanoma in the era of molecular profilingJohn F Thompson, Richard A Scolyer, Richard F Kefford
Melanoma Management|September 8, 2018
Immune checkpoint inhibitors in melanomaAdam J Cooper, Matteo S Carlino, Richard F Kefford
Pageof 14

Showing results (1-10 of 139) with videos related to

Sort By:
Pageof 14
The Medical Journal of Australia|November 6, 2012
Drug treatment for melanoma: progress, but who pays? CommentRichard F Kefford
The Medical Journal of Australia|June 14, 2006
Medical heat for climate changeRichard F Kefford
The Medical Journal of Australia|August 21, 2012
Drug treatment for melanoma: progress, but who pays?Richard F Kefford
Current Opinion in Oncology|February 26, 2003
Is there a role for genetic testing in patients with melanoma?Richard F Kefford, Graham J Mann
ANZ Journal of Surgery|January 22, 2003
Targeting molecular mechanisms in cancerRosemary L Balleine, Richard F Kefford
Cell Cycle (Georgetown, Tex.)|February 11, 2005
Enforced expression of p14ARF induces p53-dependent cell cycle arrest but not apoptosisStuart Gallagher, Richard F Kefford, Helen Rizos
Cell Cycle (Georgetown, Tex.)|May 7, 2005
p14ARF interacts with the SUMO-conjugating enzyme Ubc9 and promotes the sumoylation of its binding partnersHelen Rizos, Sarah Woodruff, Richard F Kefford
The International Journal of Biochemistry & Cell Biology|April 8, 2006
The ARF tumour suppressorStuart J Gallagher, Richard F Kefford, Helen Rizos
Lancet (London, England)|August 4, 2009
Cutaneous melanoma in the era of molecular profilingJohn F Thompson, Richard A Scolyer, Richard F Kefford
Melanoma Management|September 8, 2018
Immune checkpoint inhibitors in melanomaAdam J Cooper, Matteo S Carlino, Richard F Kefford
Pageof 14